Market Potential: Why Invest in Indonesia\u2019s Pharma and Healthcare?<\/h2>\n![\"Indonesia](\"https:\/\/investinasia.id\/blog\/wp-content\/uploads\/2025\/05\/pharmacy2.webp\")
Indonesia Pharma & Healthcare Investment Incentives (pexels.com)<\/figcaption><\/figure>\nIndonesia is home to the world\u2019s largest national health insurance scheme\u2014JKN-KIS\u2014covering over 200 million people. This fuels predictable, long-term pharmaceutical demand. With increasing pressure to localize supply chains, Indonesia aims to shift from being a net importer to a manufacturing base for essential drugs, vaccines, and medical devices.<\/p>\n
Domestic Production Over Imports<\/h3>\n
Generic drug consumption dominates due to affordability, creating an opportunity for scalable manufacturing. Industrial zones in East and West Java, Banten, and Sumatra are being optimized with enhanced utility infrastructure and logistics corridors.<\/p>\n
Digital Healthcare and Infrastructure Gaps<\/h3>\n
Telemedicine, e-pharmacies, and AI-assisted diagnostics are rising due to fragmented access in rural regions. At the same time, Indonesia\u2019s outdated hospital infrastructure has led to a USD 6 billion annual medical tourism outflow\u2014now targeted for reversal via domestic facility expansion.<\/p>\n
Strategic ASEAN Location<\/h3>\n
Indonesia\u2019s archipelagic geography offers proximity to key ASEAN markets, encouraging regional pharma logistics hubs and cross-border partnerships.<\/p>\n
Also read:<\/strong> Pharmaceutical Industry in Indonesia: Outlook and Opportunities<\/a><\/strong><\/p>\nApplicable Incentives: Tax Holidays, KEK MedTech, and Ownership Reforms<\/h2>\n\n- \n
Tax Holiday for Pharmaceutical Manufacturing<\/h3>\n<\/li>\n<\/ol>\n
Eligibility:<\/strong>
\nInvestments in \u201cpioneer industries\u201d like pharmaceutical manufacturing qualify for tax holidays<\/a> up to 20 years under PMK No. 69\/2024<\/strong>, extended through December 31, 2025<\/strong>.<\/p>\nBenefits:<\/strong><\/p>\n\n- 100% Corporate Tax Exemption<\/strong> for up to 20 years based on capital outlay<\/li>\n
- Additional 2-year tax reduction phase (50% discount post-holiday)<\/li>\n
- Pioneer status includes sectors with high technology integration and economic impact<\/li>\n<\/ul>\n
Regulatory Bodies:<\/strong><\/p>\n\n- Ministry of Finance<\/li>\n
- BKPM (Investment Coordinating Board)<\/a><\/li>\n
- Ministry of Investment<\/li>\n<\/ul>\n
Application Process: <\/strong><\/p>\nSubmit via the Online Single Submission (OSS)<\/strong> platform. Requirements include feasibility studies, fixed asset investment plan, and capital realization timelines.<\/p>\nAlso read:<\/strong> Step-by-Step: How to Qualify for Tax Holiday in Indonesia<\/a><\/strong><\/p>\n\n- \n
KEK MedTech and Special Economic Zones (SEZs)<\/h3>\n<\/li>\n<\/ol>\n
Indonesia operates 14+ Kawasan Ekonomi Khusus (KEK)<\/strong>\u2014Special Economic Zones<\/a>\u2014with unique fiscal and non-fiscal benefits. Pharma and MedTech investors can tap into tailored incentives through KEK MedTech-focused estates<\/strong>.<\/p>\nKey Benefits:<\/strong><\/p>\n\n- Extended tax holidays<\/strong> (10\u201320 years depending on investment)<\/li>\n
- PPN & import duty exemptions<\/strong> on medical equipment and raw materials<\/li>\n
- 100% foreign ownership<\/strong><\/a> in designated subsectors<\/li>\n
- Simplified immigration and customs handling<\/li>\n
- Long-term land rights (up to 95 years)<\/li>\n<\/ul>\n
Strategic KEKs for Pharma:<\/strong><\/p>\n\n- Batam and Bintan: logistics access, digital R&D<\/li>\n
- Sei Mangkei: chemical and bio-processing<\/li>\n
- Java-focused KEKs: industrial clustering and low logistics cost<\/li>\n<\/ul>\n
Also read:<\/strong> The Benefits of Investing in Indonesia\u2019s Special Economic Zones (SEZs)<\/a><\/strong><\/p>\n\n- \n
Hospital and Healthcare Facility Investments<\/h3>\n<\/li>\n<\/ol>\n
100% Foreign Ownership Allowed<\/strong><\/p>\nThanks to GR 47\/2021<\/strong> under the Omnibus Law<\/a>, foreign investors can now fully own and operate hospitals across Indonesia. Prior restrictions (67% for non-ASEAN, 75% for ASEAN) have been removed.<\/p>\nKey Provisions:<\/strong><\/p>\n\n- Reduced bed minimums for new hospitals<\/li>\n
- Mandatory provision of laboratory, blood bank, and nutrition services<\/li>\n
- Risk-based licensing model to streamline registration<\/li>\n<\/ul>\n
These policy changes support Indonesia\u2019s goal of reducing medical tourism and upgrading its domestic healthcare system.<\/p>\n
Also read:<\/strong> Risk-Based Business Licensing and OSS System in Indonesia<\/a><\/strong><\/p>\n\n- \n
Other Relevant Incentives<\/h3>\n<\/li>\n<\/ol>\n
Super Tax Deductions for R&D and Training<\/strong><\/p>\n\n- 300% deduction<\/strong> for qualifying R&D activities<\/li>\n
- 200% deduction<\/strong> for vocational training partnerships<\/li>\n
- Particularly favorable for AI, biotech, and diagnostics development<\/li>\n<\/ul>\n
Import Tax Reliefs<\/strong><\/p>\n\n- PPN and customs exemptions<\/strong> for medical equipment and essential raw material imports<\/li>\n
- Particularly beneficial for early-stage facility buildouts<\/li>\n<\/ul>\n
Also read:<\/strong> Understanding Indonesia\u2019s Super Deduction Tax for R&D and Training<\/a><\/strong><\/p>\nEntry Strategy: How to Access the Market<\/h2>\n![\"Indonesia](\"https:\/\/investinasia.id\/blog\/wp-content\/uploads\/2025\/05\/pharmacy.webp\")
Indonesia Pharma & Healthcare Investment Incentives (pexels.com)<\/figcaption><\/figure>\n\n- \n
Choose the Right KEK or Region<\/h3>\n<\/li>\n<\/ol>\n
Align your business model with zone specialization. For pharma production, regions with gas pipeline access and logistics infrastructure (e.g., West Java, Banten) are ideal.<\/p>\n
\n- \n
Leverage the OSS System<\/h3>\n<\/li>\n<\/ol>\n
Use the Online Single Submission (OSS)<\/strong><\/a> portal to apply for:<\/p>\n\n- Investment registration<\/li>\n
- Tax holidays\/allowance<\/li>\n
- Business and operational licenses<\/li>\n<\/ul>\n
\n- \n
Partner with Local Institutions<\/h3>\n<\/li>\n<\/ol>\n
Strategic alliances with Indonesian universities or R&D centers may increase eligibility for R&D super deductions and improve regulatory goodwill.<\/p>\n
\n- \n
Regulatory Readiness<\/h3>\n<\/li>\n<\/ol>\n
Prepare full documentation (feasibility study, DER compliance, KBLI classification, capital adequacy) to avoid delays and qualify for pioneer sector recognition.<\/p>\n
Conclusion: Seizing the 2025 Window<\/h2>\n
With strong macroeconomic fundamentals, government commitment to healthcare reform, and comprehensive fiscal support, 2025 is a strategically favorable year to invest in Indonesia\u2019s pharmaceutical and healthcare sectors. Those who move early to align with KEK MedTech zones and capitalize on extended tax holidays will be well-positioned for sustainable, high-yield operations in Southeast Asia\u2019s most populous market.<\/p>\n\t\t
\n\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t![\"pt](\"https:\/\/investinasia.id\/blog\/wp-content\/uploads\/2023\/05\/pt-pma-kitas-package.jpeg\" "\\"pt")
\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\nIf you are considering starting a business in Indonesia, there are a number of resources and support services available to help you get started.<\/p>\n
InvestinAsia is among the companies that specialize in aiding you with\u00a0Indonesia company registration<\/a><\/strong>. We boast a team of seasoned experts who can guide you throughout the process of:<\/p>\n\n- Foreign company \/ PMA registration in Indonesia<\/a><\/li>\n
- Indonesia representative office registration<\/a><\/li>\n
- PT PMDN Set Up<\/a><\/li>\n
- Virtual office setup in Indonesia<\/a><\/li>\n
- Business registration number in Indonesia<\/a><\/li>\n
- Indonesian Business Licenses<\/a><\/li>\n
- Indonesia Trademark Registration<\/a><\/li>\n
- Indonesia Tax Consultant and Compliance Services<\/a><\/li>\n<\/ul>\n
If you are interested in starting a business in Indonesia, you can start by contacting us for FREE consultation<\/a><\/strong>.<\/p>\n <\/p>\n
Frequently Asked Questions (FAQs)<\/h2>\nWhat is the main incentive for pharma investors in Indonesia?<\/h3>\n
Eligible pioneer industries can benefit from a full exemption on corporate income tax for a period of up to 20 years through the tax holiday program.<\/p>\n
Can foreign companies own hospitals in Indonesia?<\/h3>\n
Yes, since 2021, foreign investors have been permitted to fully own hospitals in Indonesia under Government Regulation No. 47\/2021.<\/p>\n
What is KEK MedTech?<\/h3>\n
KEK MedTech refers to specialized zones within Indonesia\u2019s SEZ framework focused on medical technology, offering tax and operational incentives.<\/p>\n
How do I apply for tax incentives?<\/h3>\n
All applications go through the OSS (Online Single Submission) system, overseen by BKPM and the Ministry of Investment.<\/p>\n
What are the requirements to qualify for a tax holiday?<\/h3>\n
Investment size (min. Rp 500 billion), pioneer industry classification, Indonesian legal entity status, and timely realization of capital investment.<\/p>\n
<\/p>\n
References:<\/strong><\/p>\n\n- pajak.com<\/a><\/li>\n
- aseanbriefing.com<\/a><\/li>\n
- kemenkeu.go.id<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"
Indonesia\u2019s pharma and healthcare sectors are among the most promising fields for investment. Backed by strong demographic trends, universal healthcare expansion, and supportive fiscal policy, foreign and domestic investors benefit … <\/p>\n","protected":false},"author":1,"featured_media":15411,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-15410","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-investment"],"acf":[],"yoast_head":"\n
Indonesia Pharma & Healthcare Investment Incentives | InvestinAsia<\/title>\n<meta name=\"description\" content=\"Explore investment incentives in Indonesia's pharma and healthcare sectors, including tax holidays, KEK MedTech, and foreign ownership liberalization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Indonesia Pharma & Healthcare Investment Incentives | InvestinAsia\" \/>\n<meta property=\"og:description\" content=\"Explore investment incentives in Indonesia's pharma and healthcare sectors, including tax holidays, KEK MedTech, and foreign ownership liberalization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog - InvestinAsia\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/web.facebook.com\/profile.php?id=100087885613500\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-19T02:56:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T03:01:49+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/investinasia.id\/blog\/wp-content\/uploads\/2025\/05\/Indonesia-Pharma-Healthcare-Investment-Incentives.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"735\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Abi Mulya\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/\"},\"author\":{\"name\":\"Abi Mulya\",\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/#\\\/schema\\\/person\\\/18c30add57890afae5e52174042f35c6\"},\"headline\":\"Pharma and Healthcare Investment Incentives in Indonesia 2025: Market Outlook, Tax Holidays, and KEK MedTech Advantage\",\"datePublished\":\"2025-05-19T02:56:07+00:00\",\"dateModified\":\"2025-10-13T03:01:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/\"},\"wordCount\":1078,\"publisher\":{\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Indonesia-Pharma-Healthcare-Investment-Incentives.webp\",\"articleSection\":[\"Business and Investment\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/\",\"url\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/\",\"name\":\"Indonesia Pharma & Healthcare Investment Incentives | InvestinAsia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Indonesia-Pharma-Healthcare-Investment-Incentives.webp\",\"datePublished\":\"2025-05-19T02:56:07+00:00\",\"dateModified\":\"2025-10-13T03:01:49+00:00\",\"description\":\"Explore investment incentives in Indonesia's pharma and healthcare sectors, including tax holidays, KEK MedTech, and foreign ownership liberalization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/#primaryimage\",\"url\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Indonesia-Pharma-Healthcare-Investment-Incentives.webp\",\"contentUrl\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Indonesia-Pharma-Healthcare-Investment-Incentives.webp\",\"width\":735,\"height\":450,\"caption\":\"Indonesia Pharma & Healthcare Investment Incentives\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/indonesia-pharma-healthcare-investment-incentives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Blog\",\"item\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Business and Investment Insights\",\"item\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/business-investment\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Pharma and Healthcare Investment Incentives in Indonesia 2025: Market Outlook, Tax Holidays, and KEK MedTech Advantage\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/\",\"name\":\"InvestinAsia - News and Insight\",\"description\":\"The Market Entry Experts Indonesia\",\"publisher\":{\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/#organization\"},\"alternateName\":\"InvestinAsia - Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/#organization\",\"name\":\"InvestinAsia\",\"alternateName\":\"IIA\",\"url\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/cropped-cropped-logo-iia-dark-3.png\",\"contentUrl\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/cropped-cropped-logo-iia-dark-3.png\",\"width\":380,\"height\":100,\"caption\":\"InvestinAsia\"},\"image\":{\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/web.facebook.com\\\/profile.php?id=100087885613500\",\"https:\\\/\\\/www.instagram.com\\\/investinasia.id\\\/\",\"https:\\\/\\\/youtube.com\\\/@InvestInAsia_id\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/investinasiaid\",\"https:\\\/\\\/www.tiktok.com\\\/@investinasia.id\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/#\\\/schema\\\/person\\\/18c30add57890afae5e52174042f35c6\",\"name\":\"Abi Mulya\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a6ca7d0fdf24d43627d54db1ceb8b982d9dee9b39832e2a0b0add5aff14d3554?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a6ca7d0fdf24d43627d54db1ceb8b982d9dee9b39832e2a0b0add5aff14d3554?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a6ca7d0fdf24d43627d54db1ceb8b982d9dee9b39832e2a0b0add5aff14d3554?s=96&d=mm&r=g\",\"caption\":\"Abi Mulya\"},\"sameAs\":[\"https:\\\/\\\/investinasia.id\\\/blogauthor\\\/investinasia-renewal\\\/\"],\"url\":\"https:\\\/\\\/investinasia.id\\\/blog\\\/author\\\/investinasia-renewal\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Indonesia Pharma & Healthcare Investment Incentives | InvestinAsia","description":"Explore investment incentives in Indonesia's pharma and healthcare sectors, including tax holidays, KEK MedTech, and foreign ownership liberalization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/","og_locale":"en_US","og_type":"article","og_title":"Indonesia Pharma & Healthcare Investment Incentives | InvestinAsia","og_description":"Explore investment incentives in Indonesia's pharma and healthcare sectors, including tax holidays, KEK MedTech, and foreign ownership liberalization.","og_url":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/","og_site_name":"Blog - InvestinAsia","article_publisher":"https:\/\/web.facebook.com\/profile.php?id=100087885613500","article_published_time":"2025-05-19T02:56:07+00:00","article_modified_time":"2025-10-13T03:01:49+00:00","og_image":[{"width":735,"height":450,"url":"http:\/\/investinasia.id\/blog\/wp-content\/uploads\/2025\/05\/Indonesia-Pharma-Healthcare-Investment-Incentives.webp","type":"image\/webp"}],"author":"Abi Mulya","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/#article","isPartOf":{"@id":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/"},"author":{"name":"Abi Mulya","@id":"https:\/\/investinasia.id\/blog\/#\/schema\/person\/18c30add57890afae5e52174042f35c6"},"headline":"Pharma and Healthcare Investment Incentives in Indonesia 2025: Market Outlook, Tax Holidays, and KEK MedTech Advantage","datePublished":"2025-05-19T02:56:07+00:00","dateModified":"2025-10-13T03:01:49+00:00","mainEntityOfPage":{"@id":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/"},"wordCount":1078,"publisher":{"@id":"https:\/\/investinasia.id\/blog\/#organization"},"image":{"@id":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/#primaryimage"},"thumbnailUrl":"https:\/\/investinasia.id\/blog\/wp-content\/uploads\/2025\/05\/Indonesia-Pharma-Healthcare-Investment-Incentives.webp","articleSection":["Business and Investment"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/","url":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/","name":"Indonesia Pharma & Healthcare Investment Incentives | InvestinAsia","isPartOf":{"@id":"https:\/\/investinasia.id\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/#primaryimage"},"image":{"@id":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/#primaryimage"},"thumbnailUrl":"https:\/\/investinasia.id\/blog\/wp-content\/uploads\/2025\/05\/Indonesia-Pharma-Healthcare-Investment-Incentives.webp","datePublished":"2025-05-19T02:56:07+00:00","dateModified":"2025-10-13T03:01:49+00:00","description":"Explore investment incentives in Indonesia's pharma and healthcare sectors, including tax holidays, KEK MedTech, and foreign ownership liberalization.","breadcrumb":{"@id":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/#primaryimage","url":"https:\/\/investinasia.id\/blog\/wp-content\/uploads\/2025\/05\/Indonesia-Pharma-Healthcare-Investment-Incentives.webp","contentUrl":"https:\/\/investinasia.id\/blog\/wp-content\/uploads\/2025\/05\/Indonesia-Pharma-Healthcare-Investment-Incentives.webp","width":735,"height":450,"caption":"Indonesia Pharma & Healthcare Investment Incentives"},{"@type":"BreadcrumbList","@id":"https:\/\/investinasia.id\/blog\/indonesia-pharma-healthcare-investment-incentives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Blog","item":"https:\/\/investinasia.id\/blog\/"},{"@type":"ListItem","position":2,"name":"Business and Investment Insights","item":"https:\/\/investinasia.id\/blog\/business-investment\/"},{"@type":"ListItem","position":3,"name":"Pharma and Healthcare Investment Incentives in Indonesia 2025: Market Outlook, Tax Holidays, and KEK MedTech Advantage"}]},{"@type":"WebSite","@id":"https:\/\/investinasia.id\/blog\/#website","url":"https:\/\/investinasia.id\/blog\/","name":"InvestinAsia - News and Insight","description":"The Market Entry Experts Indonesia","publisher":{"@id":"https:\/\/investinasia.id\/blog\/#organization"},"alternateName":"InvestinAsia - Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/investinasia.id\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/investinasia.id\/blog\/#organization","name":"InvestinAsia","alternateName":"IIA","url":"https:\/\/investinasia.id\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/investinasia.id\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/investinasia.id\/blog\/wp-content\/uploads\/2023\/07\/cropped-cropped-logo-iia-dark-3.png","contentUrl":"https:\/\/investinasia.id\/blog\/wp-content\/uploads\/2023\/07\/cropped-cropped-logo-iia-dark-3.png","width":380,"height":100,"caption":"InvestinAsia"},"image":{"@id":"https:\/\/investinasia.id\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/web.facebook.com\/profile.php?id=100087885613500","https:\/\/www.instagram.com\/investinasia.id\/","https:\/\/youtube.com\/@InvestInAsia_id","https:\/\/www.linkedin.com\/company\/investinasiaid","https:\/\/www.tiktok.com\/@investinasia.id"]},{"@type":"Person","@id":"https:\/\/investinasia.id\/blog\/#\/schema\/person\/18c30add57890afae5e52174042f35c6","name":"Abi Mulya","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a6ca7d0fdf24d43627d54db1ceb8b982d9dee9b39832e2a0b0add5aff14d3554?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a6ca7d0fdf24d43627d54db1ceb8b982d9dee9b39832e2a0b0add5aff14d3554?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a6ca7d0fdf24d43627d54db1ceb8b982d9dee9b39832e2a0b0add5aff14d3554?s=96&d=mm&r=g","caption":"Abi Mulya"},"sameAs":["https:\/\/investinasia.id\/blogauthor\/investinasia-renewal\/"],"url":"https:\/\/investinasia.id\/blog\/author\/investinasia-renewal\/"}]}},"_links":{"self":[{"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/posts\/15410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/comments?post=15410"}],"version-history":[{"count":4,"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/posts\/15410\/revisions"}],"predecessor-version":[{"id":16527,"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/posts\/15410\/revisions\/16527"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/media\/15411"}],"wp:attachment":[{"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/media?parent=15410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/categories?post=15410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/investinasia.id\/blog\/wp-json\/wp\/v2\/tags?post=15410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Indonesia is home to the world\u2019s largest national health insurance scheme\u2014JKN-KIS\u2014covering over 200 million people. This fuels predictable, long-term pharmaceutical demand. With increasing pressure to localize supply chains, Indonesia aims to shift from being a net importer to a manufacturing base for essential drugs, vaccines, and medical devices.<\/p>\n
Domestic Production Over Imports<\/h3>\n
Generic drug consumption dominates due to affordability, creating an opportunity for scalable manufacturing. Industrial zones in East and West Java, Banten, and Sumatra are being optimized with enhanced utility infrastructure and logistics corridors.<\/p>\n
Digital Healthcare and Infrastructure Gaps<\/h3>\n
Telemedicine, e-pharmacies, and AI-assisted diagnostics are rising due to fragmented access in rural regions. At the same time, Indonesia\u2019s outdated hospital infrastructure has led to a USD 6 billion annual medical tourism outflow\u2014now targeted for reversal via domestic facility expansion.<\/p>\n
Strategic ASEAN Location<\/h3>\n
Indonesia\u2019s archipelagic geography offers proximity to key ASEAN markets, encouraging regional pharma logistics hubs and cross-border partnerships.<\/p>\n
Also read:<\/strong> Pharmaceutical Industry in Indonesia: Outlook and Opportunities<\/a><\/strong><\/p>\n Eligibility:<\/strong> Benefits:<\/strong><\/p>\n Regulatory Bodies:<\/strong><\/p>\n Application Process: <\/strong><\/p>\n Submit via the Online Single Submission (OSS)<\/strong> platform. Requirements include feasibility studies, fixed asset investment plan, and capital realization timelines.<\/p>\n Also read:<\/strong> Step-by-Step: How to Qualify for Tax Holiday in Indonesia<\/a><\/strong><\/p>\n Indonesia operates 14+ Kawasan Ekonomi Khusus (KEK)<\/strong>\u2014Special Economic Zones<\/a>\u2014with unique fiscal and non-fiscal benefits. Pharma and MedTech investors can tap into tailored incentives through KEK MedTech-focused estates<\/strong>.<\/p>\n Key Benefits:<\/strong><\/p>\n Strategic KEKs for Pharma:<\/strong><\/p>\n Also read:<\/strong> The Benefits of Investing in Indonesia\u2019s Special Economic Zones (SEZs)<\/a><\/strong><\/p>\n 100% Foreign Ownership Allowed<\/strong><\/p>\n Thanks to GR 47\/2021<\/strong> under the Omnibus Law<\/a>, foreign investors can now fully own and operate hospitals across Indonesia. Prior restrictions (67% for non-ASEAN, 75% for ASEAN) have been removed.<\/p>\n Key Provisions:<\/strong><\/p>\n These policy changes support Indonesia\u2019s goal of reducing medical tourism and upgrading its domestic healthcare system.<\/p>\n Also read:<\/strong> Risk-Based Business Licensing and OSS System in Indonesia<\/a><\/strong><\/p>\n Super Tax Deductions for R&D and Training<\/strong><\/p>\n Import Tax Reliefs<\/strong><\/p>\n Also read:<\/strong> Understanding Indonesia\u2019s Super Deduction Tax for R&D and Training<\/a><\/strong><\/p>\n Align your business model with zone specialization. For pharma production, regions with gas pipeline access and logistics infrastructure (e.g., West Java, Banten) are ideal.<\/p>\n Use the Online Single Submission (OSS)<\/strong><\/a> portal to apply for:<\/p>\n Strategic alliances with Indonesian universities or R&D centers may increase eligibility for R&D super deductions and improve regulatory goodwill.<\/p>\n Prepare full documentation (feasibility study, DER compliance, KBLI classification, capital adequacy) to avoid delays and qualify for pioneer sector recognition.<\/p>\n With strong macroeconomic fundamentals, government commitment to healthcare reform, and comprehensive fiscal support, 2025 is a strategically favorable year to invest in Indonesia\u2019s pharmaceutical and healthcare sectors. Those who move early to align with KEK MedTech zones and capitalize on extended tax holidays will be well-positioned for sustainable, high-yield operations in Southeast Asia\u2019s most populous market.<\/p>\n\t\t If you are considering starting a business in Indonesia, there are a number of resources and support services available to help you get started.<\/p>\n InvestinAsia is among the companies that specialize in aiding you with\u00a0Indonesia company registration<\/a><\/strong>. We boast a team of seasoned experts who can guide you throughout the process of:<\/p>\n If you are interested in starting a business in Indonesia, you can start by contacting us for FREE consultation<\/a><\/strong>.<\/p>\n <\/p>\n Eligible pioneer industries can benefit from a full exemption on corporate income tax for a period of up to 20 years through the tax holiday program.<\/p>\n Yes, since 2021, foreign investors have been permitted to fully own hospitals in Indonesia under Government Regulation No. 47\/2021.<\/p>\n KEK MedTech refers to specialized zones within Indonesia\u2019s SEZ framework focused on medical technology, offering tax and operational incentives.<\/p>\n All applications go through the OSS (Online Single Submission) system, overseen by BKPM and the Ministry of Investment.<\/p>\n Investment size (min. Rp 500 billion), pioneer industry classification, Indonesian legal entity status, and timely realization of capital investment.<\/p>\n <\/p>\n References:<\/strong><\/p>\n Indonesia\u2019s pharma and healthcare sectors are among the most promising fields for investment. Backed by strong demographic trends, universal healthcare expansion, and supportive fiscal policy, foreign and domestic investors benefit … <\/p>\n","protected":false},"author":1,"featured_media":15411,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-15410","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-investment"],"acf":[],"yoast_head":"\nApplicable Incentives: Tax Holidays, KEK MedTech, and Ownership Reforms<\/h2>\n
\n
Tax Holiday for Pharmaceutical Manufacturing<\/h3>\n<\/li>\n<\/ol>\n
\nInvestments in \u201cpioneer industries\u201d like pharmaceutical manufacturing qualify for tax holidays<\/a> up to 20 years under PMK No. 69\/2024<\/strong>, extended through December 31, 2025<\/strong>.<\/p>\n\n
\n
\n
KEK MedTech and Special Economic Zones (SEZs)<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
\n
Hospital and Healthcare Facility Investments<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Other Relevant Incentives<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Entry Strategy: How to Access the Market<\/h2>\n
\n
Choose the Right KEK or Region<\/h3>\n<\/li>\n<\/ol>\n
\n
Leverage the OSS System<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Partner with Local Institutions<\/h3>\n<\/li>\n<\/ol>\n
\n
Regulatory Readiness<\/h3>\n<\/li>\n<\/ol>\n
Conclusion: Seizing the 2025 Window<\/h2>\n
\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\n\n
Frequently Asked Questions (FAQs)<\/h2>\n
What is the main incentive for pharma investors in Indonesia?<\/h3>\n
Can foreign companies own hospitals in Indonesia?<\/h3>\n
What is KEK MedTech?<\/h3>\n
How do I apply for tax incentives?<\/h3>\n
What are the requirements to qualify for a tax holiday?<\/h3>\n
\n